270 related articles for article (PubMed ID: 23216250)
1. YB-1: oncoprotein, prognostic marker and therapeutic target?
Lasham A; Print CG; Woolley AG; Dunn SE; Braithwaite AW
Biochem J; 2013 Jan; 449(1):11-23. PubMed ID: 23216250
[TBL] [Abstract][Full Text] [Related]
2. Y-box binding protein 1--a prognostic marker and target in tumour therapy.
Kosnopfel C; Sinnberg T; Schittek B
Eur J Cell Biol; 2014; 93(1-2):61-70. PubMed ID: 24461929
[TBL] [Abstract][Full Text] [Related]
3. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
[TBL] [Abstract][Full Text] [Related]
4. Active targeting schemes for nanoparticle systems in cancer therapeutics.
Byrne JD; Betancourt T; Brannon-Peppas L
Adv Drug Deliv Rev; 2008 Dec; 60(15):1615-26. PubMed ID: 18840489
[TBL] [Abstract][Full Text] [Related]
5. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells.
Basaki Y; Taguchi K; Izumi H; Murakami Y; Kubo T; Hosoi F; Watari K; Nakano K; Kawaguchi H; Ohno S; Kohno K; Ono M; Kuwano M
Eur J Cancer; 2010 Mar; 46(5):954-65. PubMed ID: 20079629
[TBL] [Abstract][Full Text] [Related]
6. Y-box-binding protein 1 (YB-1) and its functions.
Eliseeva IA; Kim ER; Guryanov SG; Ovchinnikov LP; Lyabin DN
Biochemistry (Mosc); 2011 Dec; 76(13):1402-33. PubMed ID: 22339596
[TBL] [Abstract][Full Text] [Related]
7. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
8. MAPK and PI3K/AKT mediated YB-1 activation promotes melanoma cell proliferation which is counteracted by an autoregulatory loop.
Sinnberg T; Sauer B; Holm P; Spangler B; Kuphal S; Bosserhoff A; Schittek B
Exp Dermatol; 2012 Apr; 21(4):265-70. PubMed ID: 22417301
[TBL] [Abstract][Full Text] [Related]
9. Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer.
Shibahara K; Sugio K; Osaki T; Uchiumi T; Maehara Y; Kohno K; Yasumoto K; Sugimachi K; Kuwano M
Clin Cancer Res; 2001 Oct; 7(10):3151-5. PubMed ID: 11595709
[TBL] [Abstract][Full Text] [Related]
10. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.
Sutherland BW; Kucab J; Wu J; Lee C; Cheang MC; Yorida E; Turbin D; Dedhar S; Nelson C; Pollak M; Leighton Grimes H; Miller K; Badve S; Huntsman D; Blake-Gilks C; Chen M; Pallen CJ; Dunn SE
Oncogene; 2005 Jun; 24(26):4281-92. PubMed ID: 15806160
[TBL] [Abstract][Full Text] [Related]
11. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
[TBL] [Abstract][Full Text] [Related]
12. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
13. Strong YB-1 expression is associated with liver metastasis progression and predicts shorter disease-free survival in advanced gastric cancer.
Wu Y; Yamada S; Izumi H; Li Z; Shimajiri S; Wang KY; Liu YP; Kohno K; Sasaguri Y
J Surg Oncol; 2012 Jun; 105(7):724-30. PubMed ID: 22215526
[TBL] [Abstract][Full Text] [Related]
14. MET receptor tyrosine kinase as a therapeutic anticancer target.
Stellrecht CM; Gandhi V
Cancer Lett; 2009 Jul; 280(1):1-14. PubMed ID: 19100682
[TBL] [Abstract][Full Text] [Related]
15. Simulating the hallmarks of cancer.
Abbott RG; Forrest S; Pienta KJ
Artif Life; 2006; 12(4):617-34. PubMed ID: 16953788
[TBL] [Abstract][Full Text] [Related]
16. Targeting the tumor vascular compartment to improve conventional cancer therapy.
Feron O
Trends Pharmacol Sci; 2004 Oct; 25(10):536-42. PubMed ID: 15380938
[TBL] [Abstract][Full Text] [Related]
17. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
18. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
Wallerand H; Reiter RR; Ravaud A
Curr Opin Urol; 2008 Sep; 18(5):524-32. PubMed ID: 18670279
[TBL] [Abstract][Full Text] [Related]
19. Targeting silibinin in the antiproliferative pathway.
Li L; Zeng J; Gao Y; He D
Expert Opin Investig Drugs; 2010 Feb; 19(2):243-55. PubMed ID: 20047507
[TBL] [Abstract][Full Text] [Related]
20. The up-regulation of Y-box binding proteins (DNA binding protein A and Y-box binding protein-1) as prognostic markers of hepatocellular carcinoma.
Yasen M; Kajino K; Kano S; Tobita H; Yamamoto J; Uchiumi T; Kon S; Maeda M; Obulhasim G; Arii S; Hino O
Clin Cancer Res; 2005 Oct; 11(20):7354-61. PubMed ID: 16243807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
